Abstract Number: 482 • 2019 ACR/ARP Annual Meeting
Antibody Repertoire Sequencing, Antigen Array Analysis, and Cytokine Profiling of Blood from Individuals at High-risk for RA Reveals Candidate Immunoglobulin V Genes, ACPA, and Cytokines That May Promote the Transition to Arthritis
Background/Purpose: The “Targeting Immune Responses for Prevention of RA” (TIP-RA) collaboration studies individuals at high risk for developing rheumatoid arthritis (RA) because of serum anti-citrullinated…Abstract Number: 2269 • 2019 ACR/ARP Annual Meeting
Major Stressors in the Year Prior to Diagnosis Affects RA Characteristics at Presentation and 1 Year
Background/Purpose: Although many RA patients attribute their disease onset to recent life events, results from retrospective studies remain unclear. We compared characteristics of newly diagnosed…Abstract Number: 485 • 2019 ACR/ARP Annual Meeting
Comparison of Clinical Features, Synovial Histology and Immunohistochemistry in Seropositive Arthralgia, Rheumatoid Arthritis, and Osteoarthritis
Background/Purpose: Seropositive arthralgia is defined as joint pain in patients positive for rheumatoid factor (RF) or anti-citrullinated protein antibodies (ACPA). It is a precursor to…Abstract Number: 2324 • 2019 ACR/ARP Annual Meeting
Metabolic Syndrome and Early Arthritis: Frequency, Association with Antibodies Profile and Disease Activity
Background/Purpose: The Metabolic Syndrome (MetS) is an independent factor of cardiovascular morbidity and mortality and most studies show that its prevalence is higher in established…Abstract Number: 486 • 2019 ACR/ARP Annual Meeting
Evolution of Seropositive Arthralgia over Time: Predictors of Evolution to Rheumatoid Arthritis
Background/Purpose: Seropositive arthralgia is defined as joint pain in patients positive for rheumatoid factor (RF) or anti-citrullinated protein antibodies (ACPA). In some individuals it is…Abstract Number: 2361 • 2019 ACR/ARP Annual Meeting
Early Treatment of Rheumatoid Arthritis with Disease-Modifying Anti-Rheumatic Drugs at < 3 versus 3-6 Months from Onset of Symptoms: Results from a Cohort of Hispanics from Puerto Rico
Background/Purpose: There is no doubt that early treatment of rheumatoid arthritis (RA) with disease-modifying anti-rheumatic drugs (DMARDs) is associated with better long-term outcomes. However, the…Abstract Number: 501 • 2019 ACR/ARP Annual Meeting
EULAR Definition of “Arthralgia Suspicious for Progression to Rheumatoid Arthritis” in a Cohort of Patients Included in a Program for Rapid Diagnosis: Role of Ultrasound and Antibodies
Background/Purpose: To evaluate the performance of the EULAR definition of arthralgias suspicious for progression to rheumatoid arthritis (RA) in a group of patients admitted to…Abstract Number: 2369 • 2019 ACR/ARP Annual Meeting
Treatment Patterns with Disease Modifying Anti-rheumatic Drugs in United States Veterans with Newly Diagnosed Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis
Background/Purpose: Delays in treatment for inflammatory arthritis (IA) are associated with unfavorable outcomes, including impaired quality of life, irreversible joint damage, and disability. Our objective…Abstract Number: 512 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Upadacitinib Monotherapy in MTX-naïve Patients with Early Active RA Receiving Treatment Within 3 Months of Diagnosis: A Post-hoc Analysis of the SELECT-EARLY
Background/Purpose: Early treatment of RA within the therapeutic window (0-3 months from symptom onset), has been associated with improved clinical outcomes and physical function. However,…Abstract Number: 2370 • 2019 ACR/ARP Annual Meeting
Discontinuation of Disease Modifying Drugs in Patients with Incident Rheumatoid Arthritis
Background/Purpose: Treatment of Rheumatoid Arthritis (RA) has undergone a big change in the last two decades in strategies, objectives and therapeutic options, especially with the…Abstract Number: 623 • 2018 ACR/ARHP Annual Meeting
Step-Down-Bridge Versus Tight-Step-up Therapy in Patients with Early Rheumatoid Arthritis Lacking Poor Prognostic Factors: An Economic Point of View
Background/Purpose: In the Care in early RA (CareRA) trial, COBRA Slim, a combination of methotrexate (MTX) with a moderate-dose prednisone step-down-bridge scheme, showed a positive…Abstract Number: 2987 • 2018 ACR/ARHP Annual Meeting
RAPID Remission during the First Year in EARLY ACTIVE Rheumatoid Arthritis Is Associated with Better 5 YEARS Structural Damage Outcomes
Background/Purpose: Remission is arguably the best and ultimate therapeutic goal in early rheumatoid arthritis (ERA). ERA patients (pts) who reach rapid and sustained remission are…Abstract Number: 891 • 2018 ACR/ARHP Annual Meeting
A Phase 3, Randomized, Controlled Trial Comparing Upadacitinib Monotherapy to MTX Monotherapy in MTX-Naïve Patients with Active Rheumatoid Arthritis
Background/Purpose: To compare the clinical efficacy, including inhibition of structural damage, and safety of upadacitinib (UPA), a JAK1-selective inhibitor, as monotherapy, vs methotrexate (MTX) monotherapy,…Abstract Number: 1201 • 2018 ACR/ARHP Annual Meeting
Finger Extensor Tendon Involvement Is Frequent in Early Rheumatoid Arthritis
Background/Purpose: Finger extensor involvement (FET) at ultrasound examination (US) was previously described in patients suffering from early psoriatic arthritis. Contradictory results were published in patients…Abstract Number: 1457 • 2018 ACR/ARHP Annual Meeting
Association between Disease Activity and Radiographic Progression in the Current Treat-to-Target Paradigm of Rheumatoid Arthritis: Real World Data from the Dutch Rheumatoid Arthritis Monitoring (DREAM) Registry
Background/Purpose: Recent studies suggested a disconnect between disease activity and radiographic damage in rheumatoid arthritis (RA) patients treated with more aggressive treatment (1). Therefore, the…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 18
- Next Page »